



Substitute for form 1448A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	6	Application Number	10/642,462
-------	---	----	---	--------------------	------------

Complete if Known

Filing Date	August 15, 2003
First Named Inventor	Piomelli, Daniele
Art Unit	1623
Examiner Name	To Be Assigned
Attorney Docket Number	02307E-125510US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1.	5,596,106	A	01-21-1997	Cullinan et al.	
	2.	5,747,524		05-05-1998	Cullinan et al.	
	3.	5,847,008		12-08-1998	Doebber	
	4.	5,859,051		06-12-1999	Adams	
	5.	5,925,672		07-20-1999	Piomelli	
	6.	5,925,766	A	07-20-1999	Barth et al.	
	7.	5,962,012	A	10-05-1999	Lin	
	8.	5,985,262		11-16-1999	Haverson	
	9.	6,017,919	A	01-25-2000	Inaba et al.	
	10.	6,028,084		02-22-2000	Barth et al.	
	11.	6,088,976		05-30-2000	Briggs et al.	
	12.	6,090,636		07-16-2000	Adams	
	13.	6,090,839	A	07-16-2000	Adams	
	14.	6,096,764		08-01-2000	Lerner	
	15.	6,160,000		12-12-2000	Adams	
	16.	6,200,998		03-13-2001	Sahoo	
	17.	6,281,595		07-17-2001	Stanley	
	18.	6,271,015	B1	08-07-2001	Glulka	
	19.	6,274,608	B1	08-14-2002	Sauerberg	
	20.	6,344,474		02-05-2002	Maruzzi et al.	
	21.	6,348,498	B1	02-19-2002	Calignano	
	22.	2001/0053788	A1	12-20-2001	Lange et al.	
	23.	2002/0035150	A1	03-21-2002	Piomelli	
	24.	2003/0149082	A1	08-07-2003	Makriyannis et al.	
	25.	2003/0016081		01-23-2003	Piomelli et al.	
	26.	2003/0041340		02-27-2003	Cravatt	
	27.	2003/0195226	A1	10-16-2003	Sit et al.	
	28.	10/681,356		N/A (Filed 10-07-2003)	Piomelli et al.	
	29.	60/485,062		N/A (Filed 07-02-2003)	En et al.	no pub dates

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	30.	EP	0 578 357	B1	12-29-1993	Sanofi		<input type="checkbox"/>
	31.	EP	0 656 354	A1	06-07-1999	Sanofi	not in English	<input type="checkbox"/>
	32.	WO	97/36579	A1	10-09-1997	Willson		<input type="checkbox"/>
	33.	WO	97/27857	A1	08-07-1997	Adams		<input type="checkbox"/>
	34.	WO	97/28149	A1	08-07-1997	Liebowitz		<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/642,462		
		Filing Date	August 15, 2003		
		First Named Inventor	Piomelli, Daniele		
		Art Unit	1623		
		Examiner Name	To Be Assigned		
Sheet	2	of	6	Attorney Docket Number	02307E-125510US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	35.	WO	98/20119	A1	05-14-1998	Gluta		<input type="checkbox"/>
	36.	WO	98/24396	A1	06-11-1998	Piomelli		<input type="checkbox"/>
	37.	WO	02/080660	A2	10-17-2002	UC Regents		<input type="checkbox"/>
	38.	WO	02/080903	A1	10-2002	University of Illinois		<input type="checkbox"/>
	39.	WO	02/100403	A1	12-19-2002	Eli Lilly and Co.		<input type="checkbox"/>
	40.	WO	03/000182	A2	01-03-2003	Merck & Co.		<input type="checkbox"/>
								<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60158248

Copied from 10680373 on 07/23/2007

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/642,462
		Filing Date	August 15, 2003
		First Named Inventor	Piomelli, Daniele
		Art Unit	1623
		Examiner Name	To Be Assigned
		Attorney Docket Number	02307E-125510US
Sheet	3	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	41.	AHERN, G., "Activation of TRPV1 by the safety factor oleylethanolamide" J. Biological Chemistry 278(33):30429-30434 (Aug. 15, 2003)	
	42.	AUBOEU, D. et al., "Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferators-activated receptors and liver X receptor- α in humans" Diabetes 46:1319-1327 (1997)	
	43.	BACHUR, N. et al., "Fatty Acid Amides of Ethanolamine in Mammalian Tissues," J. Biol. Chem., (1965), Vol. 240, No. 3, pp. 1019-1024.	
	44.	BERDYSHEV, E. et al., "Stress-induced generation of N-acyl ethanolamines in mouse epidermal JB8 P+ cells," Biochem. J., (2000), Vol. 348, pp. 369-374.	
	45.	BERGER, J. and D. MOLLER, "The mechanisms of action of PPARs" Annu Rev Med 53:409-35 (2002)	
	46.	BOGER, D. et al., "Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide," PNAS, (2000), Vol. 97, No. 10, pp. 5044-5049.	
	47.	CADAS, H. et al., "Biosynthesis of an Endogenous Cannabinoid Precursor in Neurons and Its Control by Calcium and cAMP," J. Neurosci., (1996), Vol. 16, pp. 3934-3942.	
	48.	CADAS, H. et al., "Occurrence and Biosynthesis of Endogenous Cannabinoid Precursor, N-Arachidonoyl Phosphatidylethanolamine, in Rat Brain," J. Neurosci., (1997), Vol. 17, No. 4, pp. 1226-1242.	
	49.	CALIGNANO, A. et al., "Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide" Eur. J. Pharmacol. 419(2-3):191-8 (2001)	
	50.	CALIGNANO, A. et al., "Bidirectional control of airway responsiveness by endogenous cannabinoids," Nature, (2000), Vol. 406, pp. 96-101.	
	51.	CALIGNANO, A. et al., "Control of pain initiation by endogenous cannabinoids," Nature, (1998), Vol. 394, pp. 277-281.	
	52.	CHAPMAN, K., "Emerging physiological roles for N-acylphosphatidylethanolamine metabolism in plants: signal transduction and membrane protection," Chem. Phys. Lipids, (2000), Vol. 108:22, pp. 221-229.	
	53.	CHAWLA, A. et al., "Nuclear receptors and lipid physiology: opening the X-files" Science 294:1968-70 (2001)	
	54.	COLVILLE-NASH, P. et al., "Inhibition of inducible nitric oxide synthase by peroxisome proliferators-activated receptor agonists: correlation with induction of heme oxygenase 1" J. Immunology 161:978-984 (1998)	
	55.	CONTI, S. et al., "Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabixin in a model of acute inflammation in the rat," British Journal of Pharmacology, (2002), Vol. 135, pp. 181-187.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/642,462		
		Filing Date	August 15, 2003		
		First Named Inventor	Piomelli, Daniele		
		Art Unit	1623		
		Examiner Name	To Be Assigned		
Sheet	4	of	6	Attorney Docket Number	02307E-125510US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	56.	CRAVATT, B. et al., "Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides" Nature 384:83-87 (1996)	
	57.	CRAVATT, B. et al., "Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase," PNAS, (2001), Vol. 98, No. 16, pp. 9371-9376.	
	58.	DESARNAUD, F. et al., "Anandamide Amidohydrolase Activity in Rat Brain Microsomes," J. Biol. Chem., (1995), Vol. 270, No. 11, pp. 6030-6035.	
	59.	DESERGNE, B. et al., "Peroxisome proliferator-activated receptors: Nuclear control of metabolism" Endocrine Rev. 20(5):649-688 (1999)	
	60.	DEVANE, W. et al., "Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor," Science, (1992), Vol. 258, pp. 1946-1949.	
	61.	DI MARZO, V. et al., "Formation and inactivation of endogenous cannabinoid anandamide in central neurons," Nature, (1994), Vol. 372, pp. 686-691.	
	62.	DI TOMASO, E. et al., "Brain cannabinoids in chocolate" Nature 382(Aug. 22):677 (1996)	
	63.	DI TOMASO, E. et al., "Endogenous lipids that activate cannabinoid receptors. Formation and inactivation" Adv. Exp. Med. Biol. 407:335-40 (1997)	
	64.	FORMAN, B. et al., "Hypolipidemic drugs, polyunsaturated fatty acids, and eicosenoids are ligands for peroxisome proliferator-activated receptors α and δ ," PNAS, (1997), Vol. 94, pp. 4312-4317.	
	65.	FU, J. et al., "Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR- α ," Nature 425(6953):90-3 (2003)	
	66.	GAETANI, S. et al., "Modulation of meal pattern in the rat by the anorexic lipid mediator oleylethanolamide" Neuropsychopharm. 28(7):1311-6 (2003)	
	67.	GIUFFRIDA, A. and D. PIOMELLI, "Purification and High-Resolution Analysis of Anandamide and Other Fatty Acylethanolamides," in S. G. Laychock, ed. and R. P. Rubin, ed. Lipid Second Messengers, CRC Press LLC, Boca Raton, Florida, (1999), pp. 113-133.	
	68.	GIUFFRIDA, A. et al., "Dopamine activation of endogenous cannabinoid signaling in dorsal striatum," Nat. Neurosci., (1999), Vol. 2, No. 4, pp. 358-363.	
	69.	GIUFFRIDA, A. et al., "Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma," FEBS Letters, (1998), Vol. 422, pp. 373-376.	
	70.	GIUFFRIDA, A. et al., "Mechanisms of Endocannabinoid Inactivation: Biochemistry and Pharmacology," J. Pharmacol. Exp. Ther., (2001), Vol. 298, No. 1, pp. 7-14.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/642,462
		Filing Date	August 15, 2003
		First Named Inventor	Piomelli, Daniele
		Art Unit	1623
		Examiner Name	To Be Assigned
		Attorney Docket Number	02307E-125510US
Sheet	5	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	71.	GIUFFRIDA, A. et al., "Quantification of Bioactive Acylethanolamides in Rat Plasma by Electrospray Mass Spectrometry," Anal. Biochem., (2000), Vol. 280, pp. 67-93.	
	72.	GOMEZ, R. et al., "A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding" J. Neurosci. 22(21):9612-7 (2002)	
	73.	GRIFFIN, G. et al., "Cloning and Pharmacological Characterization of the Rat CB ₂ Cannabinoid Receptor," J. Pharmacol. Exp. Ther., (2000), Vol. 292, No. 3, pp. 666-694.	
	74.	HASSON, M., "The effect of low-calorie diet on pramidine [oleylethanolamide (OEA)] response in obese and non-obese adults" UCI Medical Center Clinical Trials Web Page - <u>Standard Research Recruitment Advertisement Format</u>	no pub date
	75.	JANERO, D., "Nutritional aspects of nitric oxide: human health implications and therapeutic opportunities" Nutrition 17:696-903 (2001)	
	76.	KATHURIA, S. et al., "Modulation of anxiety through blockade of anandamide hydrolysis" Nature Medicine 9(1):76-81 (2003)	
	77.	KERSTEN, S. et al., "Roles of PPARs in health and disease" Nature 405:421-424 (2000)	
	78.	KHANOLKAR, A. et al., "Structure-Activity Relationships of Anandamide, end Endogenous Cannabinoid Ligand," Life Sci., (1999), Vol. 65, No. 6/7, pp. 607-616.	
	79.	KLIEWER, S. et al., "Peroxisome proliferators-activated receptors: from genes to physiology" Recent Prog Horm Res 56:239-63 (2001)	
	80.	LOVISCACH, M. et al., "Distribution of peroxisome proliferators-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action" Diabetologia 43(3):304-11 (2000)	
	81.	MECHOULAM, R. et al., "A hunger for cannabinoids" Nature 410:763-765 (2001)	
	82.	MEMON, R. et al., "Up-regulation of peroxisome proliferators-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice" Endocrinology 141(11):4021-31 (2000)	
	83.	MOYA-CAMARENA, S. et al., "Conjugated linoleic acid activates peroxisome proliferators-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats" Biochim Biophys Acta 1436(3):331-42 (1999)	
	84.	MUDALIAR, S. and R. HENRY, "PPAR agonists in health and disease: a pathophysiological and clinical overview" Current Opin. Endocrin. Diabet. 9:285-302 (2002)	
	85.	PIOMELLI et al., "Structural determinants for recognition and translocation by the anandamide transporter", Proc. Natl. Acad. Sci. USA; May 1999; Vol. 96; pp. 5802-5807	
	86.	PIOMELLI, D. et al., "The endocannabinoid system as a target for therapeutic drugs" Trends Pharmacol Sci. 21(6):218-24 (2000)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/

Copied from 10680373 on 07/23/2007

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/642,462
		Filing Date	August 15, 2003
		First Named Inventor	Piomelli, Daniele
		Art Unit	1623
		Examiner Name	To Be Assigned
		Attorney Docket Number	02307E-125510US
Sheet	6	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	87.	PIOMELLI, D. et al., "Endogenous Cannabinoid Signaling," Neurobiol. Dis., (1998), Vol. 5, pp. 462-473 (1998)	
	88.	QUISTAD, G. et al., "Fatty Acid Amide Hydrolase Inhibition by Neurotoxic Organophosphorus Pesticides," Toxicology and Applied Pharmacology, (2001), Vol. 173, pp. 48-55.	
	89.	QUISTAD, G. et al., "Selective Inhibitors of Fatty Acid Amide Hydrolase Relative to Neuropathy Target Esterase and Acetylcholinesterase: Toxicological Implications," Toxicology and Applied Pharmacology, (2002), Vol. 179, pp. 57-63.	
	90.	RALOFF, J., "Science News Online: Food for Thought: 'Prescription-strength chocolate' at < http://www.sciencenews.org/sn_arch10_12_96/food.htm > (Visited September 10, 2003) no pub date	
	91.	RINALDI-CARMONA et al., "Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist" Life Sci., 56: 1941-1947 (1995)	
	92.	REGENTS OF THE UNIVERSITY OF CALIFORNIA, "Natural, marijuana-like chemical may provide treatment for obesity- Study in Nature shows reduced feeding, weight gain" at < http://www.ucsfhealth.com/News/Releases/obesity_marijuana.htm > November 7, 2001	
	93.	RODRIGUEZ de FONSECA, F. et al., "An anorectic lipid mediator regulated by feeding," Nature, (2001) Vol. 414, pp. 209-212.	
	94.	SCHMID, H. et al., "The N-acylation-phosphodiesterase pathway and cell signalling," Chem. Phys. Lipids, (1996), Vol. 80, pp. 133-142.	
	95.	SCHMID, P. et al., "Properties of Rat Liver N-Acylethanolamine Amidohydrolase," J. Biol. Chem., (1985), Vol. 260, No. 28, pp. 14145-14149.	
	96.	SCHOONJANS, K. et al., "The peroxisome proliferators activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation" Biochim Biophys Acta 1302 (2):93-109 (1996)	
	97.	STELLA, N. et al., "Receptor-dependent formation of endogenous cannabinoids in cortical neurons" Eur. J. Pharmacol. 425(3): 189-96 (2001)	
	98.	STICKER-KRONGRAD et al., "Nitric oxide mediates hyperphagia of obese Zucker rats: relation to specific changes in the microstructure of feeding behavior" Life Sci. 58:PL9-15 (1996)	
	99.	WILLSON, T. et al., "The PPARs: From Orphan Receptors to Drug Discovery," Journal of Medicinal Chemistry, (2000), Vol. 43, No. 4, pp. 527-550.	

60158249 v1

Examiner Signature	/Timothy Thomas/	Date Considered	03/05/2008
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES UNIQUELY CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/

Copied from 10680373 on 07/23/2007